Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rintatolimod - AIM ImmunoTech

Drug Profile

Rintatolimod - AIM ImmunoTech

Alternative Names: Ampligen; Atvogen; Mismatched double-stranded RNA - AIM ImmunoTech; Poly I:Poly C12U; Poly I:polyC12U; poly(I) poly(C12,U); Rintamod; Vaccine-adjuvant-poly-I-polyC12U; Vaccine-adjuvant-rintatolimod

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hemispherx Biopharma
  • Developer AIM ImmunoTech; National Cancer Institute (USA); Roswell Park Cancer Institute; United States Army Medical Research Institute of Infectious Diseases; University of Pittsburgh
  • Class Adjuvants; Antineoplastics; Antivirals; Oligonucleotides
  • Mechanism of Action HIV replication inhibitors; Immunostimulants; Interferon stimulants; Ribonuclease stimulants; RNA synthesis inhibitors; Toll-like receptor 3 agonists; VP35 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Ebola virus infections; HIV infections; Chronic fatigue syndrome; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Chronic fatigue syndrome
  • Phase II Colorectal cancer
  • Phase I/II Breast cancer; Influenza virus infections; Ovarian cancer; Peritoneal cancer
  • Clinical Phase Unknown Pancreatic cancer
  • Preclinical Ebola virus infections; Prostate cancer; West Nile virus infections; Zika virus infection
  • Research Coronavirus infections; Influenza A virus infections
  • Suspended HIV infections
  • No development reported Hepatitis B; Malignant melanoma; Renal cell carcinoma
  • Discontinued Smallpox; Western equine encephalitis virus infections

Most Recent Events

  • 14 Oct 2019 Roswell Park Cancer Institute in collaboration with National Cancer Institute plans a phase IIa trial for Colorectal cancer (Combination therapy, Metastatic disease) in USA in October 2019 (NCT04119830)
  • 24 Sep 2019 Rintatolimod receives clearance from US FDA for exportation to Argentina for the treatment of Chronic fatigue syndrome
  • 09 Sep 2019 Roswell Park Cancer Institute and National Cancer Institute plan a phase Ib/II trial in Breast cancer (Neoadjuvant therapy, First-line therapy, Combination therapy) in USA (IV), in September 2019 , (NCT04081389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top